# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the b...
Community health centers face operational and financial challenges three months after a cyberattack on UnitedHealth Group's...
At its regular quarterly meeting, the Board authorized payment of a cash dividend of $2.10 per share, to be paid June 25, 2024,...
JP Morgan analyst Lisa Gill maintains UnitedHealth Group (NYSE:UNH) with a Overweight and raises the price target from $546 ...